These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 5627161)

  • 1. [Treatment of arteriosclerosis obliterans with pyridinolcarbamate].
    Atsumi T; Isokane N; Yamashita S; Sano T; Odakura T; Kurai A
    Nihon Naika Gakkai Zasshi; 1967 Sep; 56(9):983-92. PubMed ID: 5627161
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
    Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
    Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
    [No Abstract]   [Full Text] [Related]  

  • 3. Pyridinolcarbamate, bradykinin antagonist, in patients suffering from arteriosclerosis obliterans and thromboangiitis obliterans (Buerger's disease); a preliminary report on the treatment of human atherosclerosis.
    Shimamoto T; Atsumi T
    Jpn Heart J; 1965 Sep; 6(5):407-15. PubMed ID: 5294603
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography].
    Motomiya T
    Nihon Naika Gakkai Zasshi; 1970 Feb; 59(2):117-25. PubMed ID: 4910199
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
    Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography.
    Motomiya T; Atsumi T; Isokane N; Yamashita S; Sano T
    Jpn Heart J; 1970 Sep; 11(5):433-49. PubMed ID: 4921577
    [No Abstract]   [Full Text] [Related]  

  • 7. [A double blind crossover trial in pyridinolcarbamate treatment of atherosclerosis obliterans].
    Yamashita S
    Nihon Naika Gakkai Zasshi; 1969 Apr; 58(4):283-92. PubMed ID: 4896659
    [No Abstract]   [Full Text] [Related]  

  • 8. Results obtained with prodectin in arteriosclerotic arterial obliteration of the lower extremities.
    Hunyi L
    Ther Hung; 1976; 24(2):67-71. PubMed ID: 982342
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of atherosclerosis obliterans with pyridinolcarbamate.
    Atsumi T; Motomiya T; Isokane N; Shimamoto T
    Jpn Heart J; 1971 Jul; 12(4):335-46. PubMed ID: 5314713
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of conservative (Prodectin) treatment and surgical intervention in arteriosclerotic obliterative diseases of the lower extremities.
    Hunyi L
    Ther Hung; 1978; 26(2):77-80. PubMed ID: 684660
    [No Abstract]   [Full Text] [Related]  

  • 11. Double-blind crossoer clinical trial of pyridinolcarbamate in peripheral arterial disease (arteriosclerosis obliterans).
    Walton KW; Craig GM; Prior P; Waterhouse JA; Skilton J
    Br Heart J; 1973 Feb; 35(2):211-9. PubMed ID: 4570447
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of pyridinolcarbamate on blood coagulation and thrombolysis in patients with arteriosclerosis obliterans].
    Hess H; Goossens N; Keil-Kuri E; Zollner R; Meyer A
    Vasa; 1972; 1(3):206-11. PubMed ID: 5076123
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of atherosclerosis by pyridinolcarbamate. Review of the history of the introduction of pyridinolcarbamate and its clinical results].
    Shimamoto T
    Rev Atheroscler (Paris); 1968; 10(3):67-84. PubMed ID: 5746502
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical pharmacologic evaluation of the antiatherosclerotic agent, pyridinolcarbamate. A double-blind crossover trial in the treatment of atherosclerosis obliterans.
    Shimamoto T; Atsumi T; Yamashita S; Motomiya T; Isokane N; Ishioka T; Sakuma A
    Am Heart J; 1970 Jan; 79(1):5-19. PubMed ID: 4903137
    [No Abstract]   [Full Text] [Related]  

  • 15. [Late results of the pyridinolcarbamate treatment of thrombotic obliterating arterial diseases of the extremities].
    Fisanovich TI; Tolstova LG
    Khirurgiia (Mosk); 1979 Sep; (9):76-80. PubMed ID: 502312
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical and plethysmographic evaluation in patients with peripheral arteriopathies treated with pyridinolcarbamate].
    Lucero Eseverri JA; Fajardo JD; Velles Aguirre L; Quijano E; Ciliberti E; Lucarelli R
    Prensa Med Argent; 1970 Apr; 57(8):394-8. PubMed ID: 5517707
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of arteriosclerotic peripheral chronic obliterating arteriopathies (A.P.C.O.) of the lower extremities with a new pharmacologic combination].
    Bagliani A; Borri P; Parravicini R
    Minerva Cardioangiol; 1975 Nov; 23(11):701-10. PubMed ID: 1223674
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapeutic efficacy of pyridinolcarbamate (Anginin) in patients with combined cerebral and peripheral arteriosclerosis].
    Majkowski J; Lysakowska-Sernicka K; Gajewska A; Bilińska-Nigot B; Ostrowski K; Semenicki K
    Neurol Neurochir Pol; 1978; 12(4):387-96. PubMed ID: 714218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical tests using pyridinol carbamate on the arterial circulation and blood coagulation in patients with arteriosclerosis obliterans].
    De Soldati L; Castro CM; Grilli H; Reussi J
    Prensa Med Argent; 1969 May; 56(12):546-53. PubMed ID: 5343928
    [No Abstract]   [Full Text] [Related]  

  • 20. [Evaluation of pyridinol carbamate treatment of coronary atherosclerosis].
    Aguirre LV; Eseverri JL; Fajardo D; Ciliberti E; Quijano E; Lucerelli R
    Prensa Med Argent; 1970 Jun; 57(16):778-83. PubMed ID: 5457375
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.